Dr. Melissa Stundick brings nearly 20 years of biotech, large pharma, government, not-for-profit, and regional partnership formation experience to AlloVir. In her role at the company, she leads all business development and partnership formation activities across the AlloVir VST portfolio as well as strategic in-licensing and M&A.

Dr. Stundick joined AlloVir from Spero Therapeutics, where she was responsible for all business development activities, including strategy development, transactions, search and evaluation, and efforts to receive non-dilutive funding from government or not-for-profit organizations. Prior to joining Spero, Dr. Stundick was the Broad Spectrum Antimicrobials Program Chief within the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), where she formed and helped manage partnerships with a portfolio of companies developing novel antibacterial, antitoxin and antiviral therapeutics. She started her career at Booz Allen Hamilton, where she consulted for Department of Defense and Department of Homeland Security clients.

Dr. Stundick received her PhD in Cell and Molecular Biology from the Johns Hopkins School of Medicine and her BS in Chemistry from Bates College. She also holds a Certificate of Intelligence Analysis from the University of Maryland.